🔴 SAB Biotherapeutics is trading 5% down in pre-market

SAB Biotherapeutics is trading at $2.74, with a -5.19% move in pre-market and no clear catalyst identified.

• No fresh company-specific announcement explaining the October 9 pre-market decline was identified.
• The latest company release, dated October 1, announced SAB-142 presentations at the Breakthrough T1D Clinical & Research Congress, running October 9–11; it does not establish a reason for this move.
• U.S. futures were higher in the provided market context, which does not clearly explain the decline.